Latest 5 articles from heartwire
- Don't routinely replace spent ICDs: Proposal
Jan 27, 2012 17:00 EDT - Data mixed on role of parents and caregivers in combating childhood obesity
Jan 27, 2012 15:00 EDT - More data needed on carotid atherosclerosis, CMS advisers agree
Jan 27, 2012 12:30 EDT - Contaminated cardiac drugs kill more than 100 in Pakistan
Jan 27, 2012 10:45 EDT - Riata Summit insights: Vigilance key to following functional but "recalled" ICD leads
Jan 27, 2012 10:00 EDT
Statins in 'healthy' patients: Blumenthal vs Redberg
Posted Jan 24, 2012
at 08:40 AM, EDT
by Seth Bilazarian
The Wall Street Journal’s debate, which pitted Dr Rita Redberg against Dr Roger Blumenthal on the issue of statins for "healthy" patients, raises numerous questions including how to define a healthy patient. Does feeling healthy constitute being healthy?
What are your thoughts on this debate?
See:
Should Healthy People Take Cholesterol Drugs to Prevent Heart Disease?
To prescribe or not to prescribe: That is the statin question, experts debate
Previous posts
Struggling with the sustainable-growth-rate "hole" (and potentially massive cuts)
1 Comments |
Posted Dec 22, 2011
at 09:25 AM, EDT by Steven
at 09:25 AM, EDT by Steven
Calling all "bottom-feeder interventionalists" who provide PCI without SOS
6 Comments |
Posted Dec 13, 2011
at 10:25 AM, EDT by Seth
at 10:25 AM, EDT by Seth
Making sense of patient compliance
2 Comments |
Posted Nov 16, 2011
at 08:55 PM, EDT by Steven
at 08:55 PM, EDT by Steven
When to bridge patients on long-term anticoagulation
No comments |
Posted Nov 16, 2011
at 10:15 AM, EDT by Steven
at 10:15 AM, EDT by Steven
Niacin in AIM-HIGH: What implications for the practitioner?
4 Comments |
Posted Nov 15, 2011
at 11:20 AM, EDT by Steven
at 11:20 AM, EDT by Steven
Also from theheart.org
About Dr Seth Bilazarian
Seth Bilazarian MD has been a Clinical and Interventional Cardiologist at Pentucket Medical Associates in Massachusetts since 1993. He is board certified in Internal Medicine, Cardiovascular Medicine, Nuclear Cardiology, Vascular Ultrasound, Interventional Cardiology, and Vascular and Endovascular Medicine.
Dr Bilazarian performs coronary and peripheral interventions at Lahey Clinic and Massachusetts General Hospital. He has been an investigator in the interventional laboratory for new devices including drug-eluting stents, distal protection devices, imaging devices (OCT and InfraRed), and anticoagulant pharmacotherapy.
Dr Bilazarian is an active participant in clinical trials in congestive heart failure, hypertension, coronary disease prevention, prediabetes management, anemia, atrial fibrillation, and anticoagulation/antiplatelet therapies in the outpatient setting. He has authored numerous papers and book chapters in clinical cardiology. He was appointed as a physician advisor to the circulatory device panel of the FDA in 2008.
Dr Bilazarian performs coronary and peripheral interventions at Lahey Clinic and Massachusetts General Hospital. He has been an investigator in the interventional laboratory for new devices including drug-eluting stents, distal protection devices, imaging devices (OCT and InfraRed), and anticoagulant pharmacotherapy.
Dr Bilazarian is an active participant in clinical trials in congestive heart failure, hypertension, coronary disease prevention, prediabetes management, anemia, atrial fibrillation, and anticoagulation/antiplatelet therapies in the outpatient setting. He has authored numerous papers and book chapters in clinical cardiology. He was appointed as a physician advisor to the circulatory device panel of the FDA in 2008.
About this blog
My intent is to create a forum for dialogue on issues pertinent to private practice cardiology around topics such as:
- Integration of new data and guidelines on inpatient and outpatient practice in clinical and interventional cardiology
- Practice approaches to the extra clinical issues in dealing with managed care insurers
- Strategies for navigating the restrictions of pharmacy benefits managers (PBMs) on pharmacologic therapies for our patients
- Experiences with restrictions on testing and imaging















Comments